Sign in

You're signed outSign in or to get full access.

Trent Webb

President, American Group at Surgery PartnersSurgery Partners
Executive

About Trent Webb

W. Trent Webb is President, American Group at Surgery Partners and has been with the company for ~15 years; he became American Group President in September 2024, is 45 years old, and holds a BBA and MAcc from the University of Tennessee . Company performance under the current leadership team in 2024: revenues rose 13.5% to $3.11B and Adjusted EBITDA increased 16.0% to $508.2M, providing the backdrop for incentive plan outcomes . The 2024 cash incentive design weighted Adjusted EBITDA 70%, Net Revenue 15%, and Free Cash Flow 15%, with payouts ultimately below target and partially settled in restricted stock .

Past Roles

OrganizationRoleYearsStrategic Impact
Surgery PartnersSenior Vice President, Operations – Central RegionNot disclosedLed regional operations immediately prior to appointment as American Group President
Surgery PartnersOperations and Finance leadership rolesNot disclosedBroad, multi-functional operating and finance experience over 15 years with the company

External Roles

OrganizationRoleYearsStrategic Impact
Ernst & Young LLP (Nashville)Auditor/Consultant focused on acute care healthcare clients7 yearsHealthcare-focused financial and controls expertise prior to Surgery Partners

Fixed Compensation

  • No executive-specific base salary, target bonus %, or perquisites are disclosed for Trent Webb in the latest proxy statement. The Compensation Committee maintains a well-balanced program with cash and equity, limited perquisites, hedging prohibitions, and an executive compensation recovery (clawback) policy .

Performance Compensation

Metric2024 Weighting2024 Target2024 ActualPayout Notes
Adjusted EBITDA ($mm)70% $510.0 $508.2 Awards paid below target; a portion settled in time-based restricted stock vesting in 1 year
Net Revenue ($mm)15% $3,063.0 $3,110.0 Same payout approach as above
Free Cash Flow ($mm)15% $150.0 Below threshold No payout for FCF portion below threshold
  • Group Presidents’ annual cash incentives incorporate 50% company metrics and 50% group-specific goals; the group-specific component must reach at least 25% of target to earn any payout .

  • Long-term incentives under the plan use a mix of time-based restricted stock (typically vesting ratably over 3 years) and PSUs that cliff vest after three years based on achieving multi-year Adjusted EBITDA goals, with up to 300% payout and a TSR modifier (10–20% depending on grant year) .

Equity Ownership & Alignment

  • Hedging prohibited across employees, officers and directors; insider trading policy restricts derivatives or transactions designed to offset declines in Company stock .
  • Share ownership and retention guidelines apply to NEOs and non-employee directors (CEO: 5× salary; other NEOs: 3×; directors: 5× retainer). The proxy does not explicitly extend these guidelines to non-NEO executive officers like Webb .

Historical ownership snapshot (2015, pre-current role):

ItemValueSource
Ownership % (Annex A)0.04%
Unvested Class B Units27,410
Restricted Common Stock (Surgery Partners, Inc.)6,150 shares

Note: The above holdings are from a 2015 filing and may have changed materially; no current beneficial ownership for Webb is disclosed in the 2024–2025 proxies .

Employment Terms

  • Equity award terms (Company-wide plan): RSAs typically vest ratably over 1–3 years; PSUs have a performance period (often one year of achievement with subsequent vesting over two years or a three-year cliff) and can pay from 0% to 300% based on performance and market/TSR modifiers; accelerated vesting of earned shares can occur upon certain terminating events, including change in control .
  • Change-in-control protections emphasize double-trigger for options and restricted stock; PSUs earned as of the change-in-control date may continue to vest based on time, or accelerate if not assumed .
  • NEO severance (illustrative of Company practice): 12 months base salary, target bonus, and continued health and welfare benefits; COBRA and timing vary by executive, with lump-sum if within the change-in-control window .
  • Restrictive covenants: 1-year non-compete and 2-year non-solicitation for NEOs; executive agreements include confidentiality and IP assignment provisions .

Investment Implications

  • Alignment signals: Multi-year, performance-weighted LTI design with double-trigger CIC and an active clawback policy merit positive governance marks; hedging prohibitions reduce misalignment risk . 2024 say‑on‑pay support (~95%) indicates broad shareholder acceptance of pay design for named officers .
  • Retention and execution: Webb’s 15-year tenure, cross-functional operations/finance background, and EY healthcare experience support domain execution capabilities . Group President incentives tied partly to group-specific metrics can sharpen execution accountability .
  • Data gaps and monitoring: No current Form 4 data or proxy-reported ownership for Webb were available; attempts to fetch insider trades (Form 4) for Webb encountered an authorization error. We searched 8‑K Item 5.02 appointments/compensatory filings but found no disclosure naming Webb; monitor future 8‑Ks or proxies for employment agreement terms, grants, and ownership updates .